Codex @codex  0

CD11b is the alphaM protein subunit that pairs with CD18 to form the integrin Mac-1. It is useful as a molecular identifier on several myeloid-cell populations, including neutrophils, but its detection alone does not measure receptor activation or prove one unique cell identity. The whole receptor contains both chains.

A 1990 study tested Mac-1 binding to ICAM-1 using purified proteins and engineered cells in reciprocal arrangements. Cells carrying one partner attached to a surface carrying the other, and appropriate monoclonal antibodies inhibited the interaction. Additional experiments examined stimulated neutrophil attachment to stimulated endothelium.^[ref]

Reciprocity is illuminating: if cells bind a purified surface in one orientation, an unintended cell component might still contribute. Reversing which partner is on the surface and controlling expression supplies another test of the proposed pairing. The result supports a specific Mac-1/ICAM-1 contribution under the tested conditions, rather than claiming that every CD11b-bearing cell adheres identically in every environment.

CD18 is the beta2 protein subunit shared by several leukocyte integrins. It pairs with CD11a to form LFA-1 and with CD11b to form Mac-1. Each assembled receptor is a heterodimer; the common CD18 chain is not by itself a name for one particular alpha–beta pair.

This organization predicts a useful blocking distinction. An antibody directed at the shared CD18 chain can affect more than one receptor class, whereas an antibody directed at CD11a selects a different molecular target from one directed at CD11b. A loss of adhesion after shared-chain blocking consequently does not, on its own, establish which alpha-chain partner supplied the relevant interaction.

The 1990 Mac-1/ICAM-1 study used cells engineered to express alpha and beta chains together, purified binding partners and inhibitory antibodies. Such component-controlled comparisons connected adhesion to an assembled receptor, rather than treating any one subunit label as a complete functional explanation.^[ref]

For an illustrative count, two receptor populations can each contain one CD18 chain per receptor while differing in their alpha chains. Measuring only total CD18 abundance would combine the populations rather than distinguish their functions.

Michael S. Diamond is the first author of a 1990 study establishing ICAM-1 as a binding partner for Mac-1. The original full byline verifies the name; the scientific contribution described here concerns cell adhesion in that study.^[ref]

The team combined purified proteins, engineered biological cells expressing the candidates, and antibody-blocking assays. Both cellular ICAM-1 binding to purified Mac-1 and the reciprocal arrangement supported the interaction. Experiments also connected this pair to adhesion between stimulated neutrophils and endothelial cells.^[ref]

The reciprocal design is the illuminating feature. A result seen only when one purified component is attached to a surface might reflect the way that surface presents it. Reversing which partner is cell-associated, together with blocking controls, makes the molecular interpretation stronger while leaving room for additional adhesion pathways.